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osting by EAbstract In the present work, we report the condensation of 5-aminobenzimidazoles with b-keto-
esters leading to some new imidazo-[4,5-f]-quinoline derivatives. Based on the open chain interme-
diates obtention, the structure of the obtained imidazo-[4,5-f]-quinoline product has been discussed.
ª 2009 King Saud University. All rights reserved.1. Introduction
It has been reported that some imidazoquinoline derivatives
present pharmacological activities as immunomodulators
(Kshirsagar et al., 2006; Smith et al., 2003; Hemmi et al.,
2002). Some works based on the synthesis of these heterocy-
cles, in which structural details are different (Spencer et al.,
1977; Snyder et al., 1977; Alaimo et al., 1978; Spencer et al.,
1975; Ichiwata and Shiokawa, 1969a,b; Mullok et al., 1970)
lead us to report our contribution to these works by our
research program on benzimidazole series (El Kihel et al.,
1999a,b; Benchidmi et al., 1995).
The present work report the synthesis of imidazo-[4,5-f]-
quinoline derivatives. The condensation of 5-aminobenzimi-o.fr (A. El kihel).
ity. All rights reserved. Peer-
d University.
lsevierdazoles with b-ketoesters leads to imidazoquinoline presenting
one of the following two structures A or B (Fig. 1).
Thus, we have realized these condensations and studied the
structure of the obtained compounds with spectroscopic data:
NMR (1H, 13C) and mass.
Bobosiket al. (1992) have studied the condensation of
5-aminobenzimidazole with alkoxymethylene derivatives that
give the products of nucleophilic substitution undergo thermal
cyclizations to the corresponding imidazoquinolinones.
2. Results and discussion
2.1. Synthesis of open chain crotonic intermediates 3(a–f)
The open chain crotonic intermediates 3(a–f) has been synthe-
sized by condensation of 5-aminobenzimidazoles 1(a–c) with
b-ketoesters 2(a–b) by heating of starting material at a temper-
ature of 80 C in order to avoid the formation of the other
open chain amidic intermediate resulting of the attack of
NH2 on ester group (Scheme 1).
The structure of compounds 3(a–f) has been established by
spectroscopic data: NMR (1H, 13C) and mass.
The proton NMR spectra of these compounds present,
in particular, one system ABX corresponding to protons in
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Figure 1 Different previous products A and B of cyclization of
the open chain intermediates.
10 A. El kihel et al.positions 4, 6 and 7 as well as one singlet corresponding to
vinylic proton.
2.2. Synthesis of imidazo-[4,5-f]-quinolines 4(a–f)
The synthesis of imidazo-[4,5-f]-quinolines 4(a–f) has been
realized by cyclisation of the open chain crotonic intermediates
3(a–f) in the ethyl acetylacetate by reﬂux heating of substrates
during 6 hours (Scheme 2).The structure of imidazo-[4,5-f]-
quinolines 4(a–f) has been established by spectroscopic data:
NMR (1H, 13C), mass and analytical data.
The proton NMR spectres show the presence of one system
AB corresponding to protons H8 and H9, one singlet corre-
sponding to quinolinic proton. The structure of the exclusive
product was conﬁrmed by the isolation of the crotonic open
chain intermediate which was selectively cyclised in position
4 instead of position 6. This result differ signiﬁcantly from
those which have been described and shows that the site the
more reactive is the position 5 or 6 (El Kihel et al., 1999b;
Benchidmi et al., 1995).
3. Conclusion
The results reported in this work concerning the condensation
of 5-aminobenzimidazoles with b-ketoesters leading to new
1H-imidazo-[4,5-f]-quinoline derivatives. The structures of
the obtained compounds were established without problem
by spectroscopic data of proton and carbon 13 NMR, mass.
The open chain intermediates are useful in this reaction and
the regioselectivity of the cyclization has been demonstrated
by spectroscopic data.
4. Experimental
All compounds were characterized by their 1H-NMR and 13C-
NMR spectra as well as by microanalysis and HRMS spectra.
NMR spectra were recorded on Bruker ARX 200 (200 MHzN
H
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Schemefor 1H and 50.3 MHz for 13C) spectrometer (d-ppm/TMS, J-
Hz); for 13CNMR, the multiplicities were determined through
DEPT. Microanalysis were performed by the ‘‘Laboratoire
Central de Microanalyse du CNRS’’ (Lyon). Mass spectra
were recorded on a Varian MAT 311 spectrometer. Melting
points were measured using a Ko¨ﬂer apparatus and were
uncorrected. Column chromatography was carried out by
use of silica gel 60 Merck (230–400 Mesh).
4.1. Reaction of 5-aminobenzimidazoles 1(a–c) with 1,3-
difunctional compounds
A mixture of 5-aminobenzimidazoles 1(a–c) (4.6 mmol) and
1,3-difunctional compounds (12.5 mmol) was heated with a
steam bath at 80 C until dissolution. The mixture was kept
at this temperature for 2 hours. The crude product was ﬁltered
and recrystallised from ethanol.
4.1.1. Ethyl 3-[6-(benzimidazolyl)amino]but-2-enoate 3a
Yield = 75%; mp = 160–162 C. 1HNMR (DMSO-d6): 1.22
(t, 3H, CH3); 1.97 (s, 3H, CH3); 4.09 (q, 2H, CH2); 4.69 (s,
1H, ‚CH); 7.47 (d, 1H, H4); 7.16 (dd, 1H, H6); 7.64 (d, 1H,
H7); 8.29 (s, 1H, H2); 10.39 (s, 1H, NH). 13CNMR (DMSO-
d6): 14.5 (CH3); 19.8 (CH3); 58.1 (CH2); 83.5 (‚CH); 84.5,
119.9; 121.2 (ArCH); 159.0 (CH-2); 133.2, 142.9, 160.0; 165.2
(ArC); 169.6 (CO2). HRMS, m/z: 245 (M), calcd for C13H15-
N3O2: 245.1165, found: 245.116.
4.1.2. Ethyl 3-[6-(2-methylbenzimidazolyl)amino]but-2-enoate
3b
Yield = 73%; mp = 142–144 C. 1HNMR (DMSO-d6): 1.21
(t, 3H, CH3); 1.93 (s, 3H, CH3); 2.40 (s, 3H, CH3); 4.10 (q,
2H, CH2); 4.66 (s, 1H, ‚CH); 7.31 (d, 1H, H
4); 6.96 (dd,
1H, H6); 7.47 (d, 1H, H7); 10.34 (s, 1H, NH). 13CNMR
(DMSO-d6): 14.4 (CH3); 14.5 (CH3); 19.7 (CH3); 57.9 (CH2);
84.1 (‚CH); 118.8, 119.1; 122.2 (ArCH); 132.4, 133.7, 159.1;
160.0 (ArC); 152.3 (C-2); 169.4 (CO2). HRMS, m/z: 259 (M),
calcd for C14H17N3O2: 259.1321, found: 259.132.
4.1.3. Ethyl 3-[6-(2-ethylbenzimidazolyl)amino]but-2-enoate
3c
Yield = 69%; mp = 130–132 C. 1HNMR (DMSO-d6): 1.21
(t, 3H, CH3); 1.34 (t, 3H, CH3); 1.94 (s, 3H, CH3); 2.85 (q,
2H, CH2); 4.08 (q, 2H, CH2); 4.70 (s, 1H, ‚CH); 7.33 (d,
1H, H4); 6.96 (dd, 1H, H6); 7.49 (d, 1H, H7); 10.35 (s, 1H,
NH). 13CNMR (DMSO-d6): 12.1 (CH3); 14.4 (CH3); 19.7
(CH3); 21.9 (CH2); 57.9 (CH2); 84.0 (‚CH); 116.9, 118.1,80°C
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Condensation of 5-aminobenzimidazoles with b-ketoester 11123.1 (ArCH); 132.4, 133.1, 157.2; 160.0 (ArC); 156.9 (C-2);
169.4 (CO2). HRMS, m/z: 273 (M), calcd for C15H19N3O2:
273.1478, found: 273.147.
4.1.4. Ethyl 3-[6-(benzimidazolyl)amino]-3-phe´nylprop-2-
enoate 3d
Yield = 70%; mp = 202–204 C. 1HNMR (DMSO-d6): 1.25
(t, 3H, CH3); 4.15 (q, 2H, CH2); 4.93 (s, 1H, ‚CH); 6.97 (d,
1H, H4); 6.74 (dd, 1H, H6); 7.22 (d, 1H, H7); 7.35 (m, 5H,
Har); 8.13 (s, 1H, H
2); 10.32 (s, 1H, NH). 13CNMR (DMSO-
d6): 14.4 (CH3); 58.8 (CH2); 89.6 (‚CH); 118.4, 120.3,
123.5, 128.1, 128.5; 129.5 (ArCH); 142.4(CH-2); 130.8, 134.8,
135.7, 159.5; 165.2 (ArC); 169.2 (CO2). HRMS, m/z: 307
(M), calcd for C18H17N3O2: 307.1321, found: 307.132.
4.1.5. Ethyl 3-[6-(2-methylbenzimidazolyl)amino]-3-phenyl-
prop-2-enoate 3e
Yield = 68%; mp = 158–160 C. 1HNMR (DMSO-d6): 1.24
(t, 3H, CH3); 2.41 (s, 3H, CH3); 4.15 (q, 2H, CH2); 4.91 (s,
1H, ‚CH); 6.82 (d, 1H, H4); 6.67 (dd, 1H, H6); 7.18 (d, 1H,
H7); 7.24 (m, 5H, Har); 10.31 (s, 1H, NH).
13CNMR
(DMSO-d6): 14.4 (CH3); 14.5 (CH3); 58.7 (CH2); 89.2
(‚CH); 117.6, 119.8, 123.2, 128.1, 128.4; 129.4 (ArCH);
131.1, 134.0, 135.7, 159.6; 161.2 (ArC); 151.8 (C-2); 169.2
(CO2). HRMS, m/z: 321 (M), calcd for C19H19N3O2:
321.1478, found: 321.147.
4.1.6. Ethyl 3-[6-(2-ethylbenzimidazolyl)amino]-3-phenylprop-
2-enoate 3f
Yield = 75%; mp = 144–146 C. 1HNMR (DMSO-d6): 1.24
(t, 3H, CH3); 1.27 (t, 3H, CH3); 2.75 (q, 2H, CH2); 4.15 (q,
2H, CH2); 4.91 (s, 1H, ‚CH); 6.84 (d, 1H, H
4); 6.67 (dd,
1H, H6); 7.20 (d, 1H, H7); 7.34 (m, 5H, Har); 10.32 (s, 1H,
NH). 13CNMR (DMSO-d6): 12.0 (CH3); 14.3 (CH3); 21.8
(CH2); 58.6 (CH2); 89.1 (‚CH); 117.6, 118.8, 122.2, 128.1,
128.5; 129.7 (ArCH); 131.5, 134.1, 135.8, 155.8; 159.6(ArC);
151.6 (C-2); 169.2 (CO2). HRMS, m/z: 335 (M), calcd for
C20H21N3O2: 335.1634, found: 335.163.
4.2. Formation of the cyclised products
The open chain intermediates 3(a–f) (2.4 mmol) and ethyl ace-
toacetate (3.6 mmol) were heated under reﬂux for 5 h. After
cooling, the obtained solid product was ﬁltered off. The solid
was chromatographed on silica gel (eluent: CH2Cl2/MeOH
95/5), then recrystallised from DMF.4.2.1. 4-Hydroxy-6-methyl-1H-imidazo-[4,5-f]-quinoline 4a
Yield = 84%; mp = 344–346 C. 1HNMR (DMSO-d6–TFA):
2.42 (s, 3H, CH3); 6.11 (s, 1H, H
5); 7.39 (d, 1H, H9,
JAB = 8.8 Hz); 7.96 (d, 1H, H
8, JAB = 8.8 Hz); 8.16 (s, 1H,
H2). 13CNMR (DMSO-d6–TFA): 19.3 (CH3); 108.3 (‚CH);
121.2, 122.5 (ArCH); 129.7, 132.3, 144.2; 155.6 (ArC); 141.0
(CH-2); 148.5 (N‚C); 176.5 (C–O). HRMS, m/z: 199 (M),
calcd for C11H9N3O: 199.0751, found: 199.075. Analysis:
C11H9N3O (199.2); calcd. C, 66.32; H, 4.55; N, 21.09; found
C, 66.46; H, 4.41; N, 21.18.
4.2.2. 4-Hydroxy-2,6-dimethyl-1H-imidazo-[4,5-f]-quinoline 4b
Yield = 82%; mp > 400 C. 1HNMR (DMSO-d6–TFA): 2.74
(s, 3H, CH3); 2.94 (s, 3H, CH3); 7.00 (s, 1H, H
5); 7.84 (d, 1H,
H9, JAB = 9.0 Hz); 8.17 (d, 1H, H
8, JAB = 9.0 Hz).
13CNMR
(DMSO-d6–TFA): 11.8 (CH3); 19.5 (CH3); 108.5 (‚CH);
116.5, 119.7 (ArCH); 124.6, 127.7, 137.4; 142.2 (ArC); 155.1
(N‚C); 151.8 (C-2); 169.5 (C–O). HRMS, m/z: 213 (M), calcd
for C12H11N3O: 213.0907, found: 213.091. Analysis:
C12H11N3O (213.2); calcd. C, 67.59; H, 5.20; N, 19.71; found
C, 67.76; H, 5.11; N, 19.58.
4.2.3. 2-Ethyl-4-hydroxy-6-methyl-1H-imidazo-[4,5-f]-
quinoline 4c
Yield = 82%; mp = 308–310 C. 1HNMR (DMSO-d6–TFA):
1.20 (t, 3H, CH3); 2.51 (s, 3H, CH3); 3.02 (q, 2H, CH2); 7.02 (s,
1H, H5); 7.74 (d, 1H, H9, JAB = 9.0 Hz); 7.94 (d, 1H, H
8,
JAB = 9.0 Hz).
13CNMR (DMSO-d6–TFA): 13.6 (CH3); 23.4
(CH3); 23.8 (CH2); 110.7 (‚CH); 111.8; 122.2 (ArCH);
125.2, 128.5, 132.5; 143.5 (ArC); 161.3 (N‚C); 142.1 (C-2);
171.5 (C–O). HRMS, m/z: 227 (M), calcd for C13H13N3O:
227.1064, found: 227.106. Analysis: C13H13N3O (227.3); calcd.
C, 68.70; H, 5.77; N, 18.49; found C, 68.76; H, 6.81; N, 18.38.4.2.4. 4-Hydroxy-6-phenyl-1H-imidazo-[4,5-f]-quinoline 4d
Yield = 79%; mp = 320–322 C. 1HNMR (DMSO-d6–TFA):
6.59 (s, 1H, H5); 7.60 (m, 3H, Har); 7.72 (d, 1H, H9,
JAB = 8.8 Hz); 7.90 (m, 2H, H
ar); 8.07 (d, 1H, H8,
JAB = 8.8 Hz); 8.27 (s, 1H, H2). 13CNMR (DMSO-d6–
TFA): 107.7 (‚CH); 112.4, 112.7, 124.1, 127.5; 128.8 (ArCH);
129.1, 130.2, 134.4, 137.6; 138.6 (ArC); 141.4(CH-2); 149.2
(N‚C); 176.6 (C–O). HRMS, m/z: 261 (M), calcd for
C16H11N3O: 261.0907, found: 261.090. Analysis: C16H11-
N3O (261.3); calcd. C, 73.55; H, 4.24; N, 16.08; found C,
73.76; H, 4.15; N, 16.24.
12 A. El kihel et al.4.2.5. 4-Hydroxy-2-methyl-6-phenyl-1H-imidazo-[4,5-f]-
quinoline 4e
Yield = 80%; mp = 344–346 C. 1HNMR (DMSO-d6–TFA):
2.89 (s, 3H, CH3); 6.81 (s, 1H, H
5); 7.64 (m, 3H, Har); 7.91 (d,
1H, H9, JAB = 8.2 Hz); 7.91 (m, 2H, H
ar); 8.05 (d, 1H, H8,
JAB = 8.2 Hz).
13CNMR (DMSO-d6–TFA): 12.0 (CH3);
107.7 (‚CH); 111.2, 117.1, 118.5, 125.8; 126.9 (ArCH);
127.6, 129.1, 130.8, 133.1; 138.4 (ArC); 150.9 (C-2); 153.2
(N‚C); 174.3 (C–O). HRMS, m/z: 275 (M), calcd for
C17H13N3O: 275.1064, found: 275.106. Analysis: C17H13N3O
(275.3); calcd. C, 74.17; H, 4.76; N, 15.26; found C, 74.05;
H, 4.81; N 15.35.
4.2.6. 2-Ethyl-4-hydroxy-6-phenyl-1H-imidazo-[4,5-f]-
quinoline 4f
Yield = 77%; mp = 280–282 C. 1HNMR (DMSO-d6–TFA):
1.20 (t, 3H, CH3); 3.04 (q, 2H, CH2); 7.41 (s, 1H, H
5); 7.29 (m,
3H, Har); 7.92 (d, 1H, H9, JAB = 9.3 Hz); 7.49 (m, 2H, H
ar);
800 (d, 1H, H8, JAB = 9.3 Hz).
13CNMR (DMSO-d6–TFA):
13.7 (CH3); 24.0 (CH2); 110.3 (‚CH); 112.3, 122.9, 125.8,
128.7; 131.6 (ArCH); 132.8, 133.9, 134.1, 137.8; 142.7 (ArC);
161.5 (C-2); 162.1 (N‚C); 171.7 (C–O). HRMS, m/z: 289
(M), calcd for C18H15N3O: 289.1220, found: 289.122. Analysis:
C18H15N3O (289.3); calcd. C, 74.72; H, 5.23; N, 14.52; found
C, 74.66; H, 5.11; N, 14.38.
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